Congenital Heart Disease Market
Congenital Heart Disease Market - Global Industry Share, Growth, Competitive Analysis And Forecast, 2018-2023
The market for Congenital Heart Disease across the globe is expected to grow impressively during the forecast period. The factors driving the growth of the Gobal Congenital Heart Disease Market are rising prevalence of congenital heart disease and rise in adoption of minimally invasive procedures. Further, large number of dominating market players, growing demand for catheterization and application of cardiac biomarkers in congenital heart disease treatment are also considered as a major factor for driving the growth of the global congenital heart disease market during forecast period. In addition, advances and research in congenital heart disease and significant research funding for various projects are creating enormous opportunities for the global congenital heart disease market in coming years. The diagnosis and treatment for congenital heart disease has been changed significantly during the last decade. New interventional cardiology procedure and improved surgical techniques results in using minimally invasive techniques for the treatment of congenital heart disease. Adoption of minimally invasive technique reduces the patient’s surgical offence and also reduced hospital stay time.
In the US, one of the leading cause of infant deaths is congenital heart disease and accounts for more than half of all deaths from congenital anomalies across the globe. During heart development, structural defects arises which causes congenital heart disease. Congenital heart disease is the most common type of birth defect, affecting around 8 per 1000 live births in the US, approximately 25% of whom will require invasive treatment within the first year of life. This increasing prevalence of congenital heart disease is expected to increase the demand for diagnosis and treatment across the globe.
The global congenital heart disease market is analysed on the basis of geographical regions that are contributing significantly to the growth of the market. North America is estimated to be the dominating region in the global congenital heart disease market. Increasing adoption of minimally invasive procedures and large number of market players in this region is estimated to be the major factors that are backing the growth of the market. Whereas, Asia Pacific is estimated to be the fastest growing region during the forecast period. Growing demand for catheterization and application of cardiac biomarkers for the treatment of congenital heart disease are some of the major factors that are driving the growth of the congenital heart disease market in the region.
Key players of congenital heart disease market include Abbott Diagnostics, Array Biopharma, Inc., AstraZeneca Plc, Becton and Dickson & Co., BG Medicine Inc., Bio-Rad Laboratories, Boston Scientific Corporation, Covance, Critical Diagnostics, F. Hoffmann-La Roche Ltd, Glaxosmithkline PLC, Janssen Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., and Mylan N.V. These market players are increasingly competing against each other by adopting different market strategies such as merger & acquisition, partnership & collaboration and so on.
Research Methodology
The market study of global congenital heart disease market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary Sources Include
- Financial reports of companies involved in the market
- Whitepapers such as research-papers and news blogs
- Company websites and their product catalogue.
The Report is intended for Researchers in healthcare segment, medical sensor companies in the market, Investing companies, Government Organizations for overall market analysis and competitive analysis. The report provides in-depth analysis on market size, growth opportunity in market, product types. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
- Global congenital heart disease market by defect type
- Global congenital heart disease market by diagnosis
- Global congenital heart disease market by treatment
- Global congenital heart disease market by end user
The Report Covers
- Comprehensive research methodology of global congenital heart disease market.
- In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global congenital heart disease market.
- Insights about market determinants which are stimulating the global congenital heart disease market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
CHAPTER 1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISING PREVALENCE OF CONGENITAL HEART DISEASE
3.1.2. RISE IN ADOPTION OF MINIMALLY INVASIVE PROCEDURES
3.1.3. LARGE NUMBER OF DOMINATING MARKET PLAYERS
3.1.4. GROWING DEMAND FOR CATHETERIZATION
3.1.5. APPLICATION OF CARDIAC BIOMARKERS
3.2. RESTRAINTS
3.2.1. EXPENSIVE PROCEDURE
3.2.2. STRINGENT GOVERNMENT REGULATIONS
3.3. OPPORTUNITIES
3.3.1. ADVANCES AND RESEARCH IN CONGENITAL HEART DISEASE
3.3.2. SIGNIFICANT RESEARCH FUNDING FOR VARIOUS PROJECTS
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL CONGENITAL HEART DISEASE MARKET BY DEFECT TYPE
4.1.1. HEART VALVE DEFECTS
4.1.2. HEART WALL DEFECTS
4.1.3. BLOOD VESSEL DEFECTS
4.2. GLOBAL CONGENITAL HEART DISEASE MARKET BY DIAGNOSIS
4.2.1. ECHOCARDIOGRAM
4.2.2. CHEST X-RAY
4.2.3. MRI SCAN
4.2.4. OTHER
4.3. GLOBAL CONGENITAL HEART DISEASE MARKET BY TREATMENT
4.3.1. MEDICATIONS
4.3.2. IMPLANTABLE HEART DEVICES
4.3.3. CATHETER PROCEDURES
4.3.4. OPEN-HEART SURGERY
4.3.5. HEART TRANSPLANT
4.4. GLOBAL CONGENITAL HEART DISEASE MARKET BY END USER
4.4.1. HOSPITALS AND CLINICS
4.4.2. DIAGNOSTIC CENTRES
4.4.3. OTHER
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1.1. KEY COMPANY ANALYSIS
5.1.2. KEY STRATEGIC ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. ABBOTT DIAGNOSTICS
7.2. ARRAY BIOPHARMA, INC.
7.3. ASTRAZENECA PLC
7.4. BECTON AND DICKSON & CO.
7.5. BG MEDICINE INC.
7.6. BIO-RAD LABORATORIES
7.7. BOSTON SCIENTIFIC CORPORATION
7.8. COVANCE
7.9. CRITICAL DIAGNOSTICS
7.10. F. HOFFMANN-LA ROCHE LTD
7.11. GLAXOSMITHKLINE PLC
7.12. JANSSEN PHARMACEUTICALS, INC.
7.13. MEDTRONIC
7.14. MERCK & CO., INC.
7.15. MYLAN N.V.
7.16. NOVARTIS INTERNATIONAL AG
7.17. PFIZER, INC.
7.18. RANDOX LABORATORIES LTD.
7.19. RESPONSE BIOMEDICAL CORPORATION
7.20. SANOFI S.A.
7.21. SIEMENS HEALTHCARE
7.22. THERMO FISHER SCIENTIFIC INC.
7.23. VERICEL CORPORATION
LIST OF TABLES
TABLE # 1 GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2017-2023 ($ MILLION)
TABLE # 2 GLOBAL HEART VALVE DEFECTS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 3 GLOBAL HEART WALL DEFECTS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 4 GLOBAL BLOOD VESSEL DEFECT MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 5 GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 6 GLOBAL ECHOCARDIOGRAM MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 7 GLOBAL CHEST X-RAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 8 GLOBAL MRI SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 9 GLOBAL OTHER APPLICATION MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 10 GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 11 GLOBAL MEDICATIONS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 12 GLOBAL IMPLANTABLE HEART DEVICES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 13 GLOBAL CATHETER PROCEDURES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 14 GLOBAL OPEN-HEART SURGERY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 15 GLOBAL HEART TRANSPLANT MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 16 GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
TABLE # 17 GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 18 GLOBAL DIAGNOSTIC CENTRE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 19 GLOBAL OTHER END USER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 20 GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
TABLE # 21 NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 22 NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2017-2023 ($ MILLION)
TABLE # 23 NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 24 NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 25 NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
TABLE # 26 EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 27 EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2017-2023 ($ MILLION)
TABLE # 28 EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 29 EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 30 EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
TABLE # 31 APAC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 32 APAC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2017-2023 ($ MILLION)
TABLE # 33 APAC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 34 APAC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 35 APAC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
TABLE # 36 ROW CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2017-2023 ($ MILLION)
TABLE # 37 ROW CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 38 ROW CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 39 ROW CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
LIST OF FIGURES
FIGURE # 1 GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY DEFECT TYPE, 2017 VS 2023 (%)
FIGURE # 2 GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY DIAGNOSIS, 2017 VS 2023 (%)
FIGURE # 3 GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY TREATMENT, 2017 VS 2023 (%)
FIGURE # 4 GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY END USER, 2017 VS 2023 (%)
FIGURE # 5 US CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 6 CANADA CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 7 UK CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 8 FRANCE CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 9 GERMANY CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 10 ITALY CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 11 SPAIN CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 12 ROE CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 13 INDIA CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 14 CHINA CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 15 JAPAN CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 16 ROAPAC CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 17 REST OF THE WORLD CONGENITAL HEART DISEASE MARKET SIZE, 2017-2023 ($ MILLION)
